Description of ALK+ NSCLC patient characteristics and ALK testing patterns.

Wakelee, Heather A.; Sasané, Medha; Zhang, Jie; Macalalad, Alexander R.; Galebach, Philip; Jarvis, John; Kageleiry, Andrew; Huang, Qing; Culver, Kenneth W.; Wu, Eric Q.; Guérin, Annie

doi:10.1200/jco.2014.32.15_suppl.8062

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their survey of 273 ALK+ patients, they found that 33% of patients had a >10 pack year history, 33% were former smokers, and 33% were never smokers. They also found that 52% of ALK-positive patients were aged 65 years or older at diagnosis, indicating that the stereotype of a never-smoker young patient may be imperfect and therefore should not be used to determine which patients will be screened [69]. …”

Section: Discussionmentioning

confidence: 99%

The Minority Report: Targeting the Rare Oncogenes in NSCLC

McCoach

2014

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Lung cancer is still responsible for the highest number of cancer deaths worldwide. Despite this fact, significant progress has been made in the treatment of non-small cell lung cancer (NSCLC). Specifically, efforts to identify and treat genetic alterations (gene mutations, gene fusions, gene amplification events, etc.) that result in oncogenic drivers are now standard of care (EGFR and ALK) or an intense area of research. The most prevalent oncogenic drivers have likely already been identified; thus, there is now a focus on subgroups of tumors with less common genetic alterations. Interestingly, as we explore these less common mutations, we are discovering that many occur across other tumor types (i.e., non-lung cancer), further justifying their study. Furthermore, many studies have demonstrated that by searching broadly for multiple genetic alterations in large subsets of patients they are able to identify potentially targetable alterations in the majority of patients. Although individually, the rare oncogenic drivers subgroups may seem to occur too infrequently to justify their exploration, the fact that the majority of patients with NSCLC harbor a potentially actionable driver mutation within their tumors and the fact that different types of cancers often have the same oncogenic driver justifies this approach.

show abstract

Section: Discussionmentioning

confidence: 99%

The Minority Report: Targeting the Rare Oncogenes in NSCLC

McCoach

2014

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

show abstract

Description of ALK+ NSCLC patient characteristics and ALK testing patterns.

Cited by 1 publication

References 0 publications

The Minority Report: Targeting the Rare Oncogenes in NSCLC

The Minority Report: Targeting the Rare Oncogenes in NSCLC

Contact Info

Product

Resources

About